Sotera Health (SHC) Scheduled to Post Quarterly Earnings on Thursday

Sotera Health (NASDAQ:SHC) is scheduled to announce its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.12 per share for the quarter. Sotera Health has set its FY24 guidance at $0.67 to $0.75 EPS and its FY 2024 guidance at 0.670-0.750 EPS.Investors that wish to listen to the company’s conference call can do so using this link.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.26. The business had revenue of $310.24 million for the quarter, compared to analyst estimates of $302.17 million. Sotera Health had a net margin of 4.90% and a return on equity of 51.32%. The company’s revenue was up 23.3% on a year-over-year basis. During the same quarter last year, the firm earned $0.23 EPS. On average, analysts expect Sotera Health to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Sotera Health Price Performance

Shares of Sotera Health stock opened at $11.27 on Thursday. The firm has a market cap of $3.19 billion, a PE ratio of 62.61 and a beta of 2.11. Sotera Health has a 12-month low of $10.71 and a 12-month high of $19.40. The company has a quick ratio of 2.21, a current ratio of 2.42 and a debt-to-equity ratio of 5.16. The company’s fifty day simple moving average is $13.20 and its two-hundred day simple moving average is $14.13.

Analysts Set New Price Targets

A number of equities research analysts have issued reports on SHC shares. Barclays cut their price target on shares of Sotera Health from $19.00 to $14.00 and set an “overweight” rating on the stock in a report on Wednesday, April 10th. Jefferies Financial Group raised shares of Sotera Health from a “hold” rating to a “buy” rating and lifted their target price for the company from $15.00 to $15.50 in a research note on Monday, March 25th. KeyCorp started coverage on shares of Sotera Health in a research note on Tuesday, February 6th. They set a “sector weight” rating on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $20.00 target price on shares of Sotera Health in a research note on Monday, March 4th. Finally, TheStreet raised shares of Sotera Health from a “d” rating to a “c-” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $17.70.

Insider Activity

In related news, insider Michael P. Rutz sold 83,109 shares of Sotera Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the completion of the transaction, the insider now directly owns 544,409 shares of the company’s stock, valued at approximately $7,790,492.79. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Pincus & Co. Warburg sold 16,594,363 shares of Sotera Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $237,465,334.53. Following the completion of the transaction, the director now directly owns 88,822,952 shares of the company’s stock, valued at approximately $1,271,056,443.12. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Michael P. Rutz sold 83,109 shares of Sotera Health stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $14.31, for a total transaction of $1,189,289.79. Following the transaction, the insider now directly owns 544,409 shares of the company’s stock, valued at $7,790,492.79. The disclosure for this sale can be found here. Insiders own 55.12% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.